Yin-Shan Ng

Therapeutic angiogenesis for cardiovascular disease.

Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.

Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis.

Tales of the cryptic: unveiling more angiogenesis inhibitors.

Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms.

Won't you be my neighbor? Local induction of arteriogenesis.

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

VEGF expression is downregulated in nitrofen-induced congenital diaphragmatic hernia.

Identification of genes involved in VEGF-mediated vascular morphogenesis using embryonic stem cell-derived cystic embryoid bodies.

VEGF function in vascular pathogenesis.

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis.

Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.

RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.

Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model.

The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.

Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular injury in a porcine model.

Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.

VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.

Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model.

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.